Another study, this time carried out in India, demonstrates that the antibodies produced by vaccination against covid-19 significantly decay after four months of application.
The study, also released in the format of preprint, without peer review, followed 614 people vaccinated with two different immunizers: Covishield, developed by Oxford/AstraZeneca, and Covaxin, developed by the Indian laboratory Bharat Biotech.
It is worth noting that, despite the drop in antibodies, the vaccine produces other types of defenses in the body. It is able to induce the production of memory cells that are quickly activated in case of infection and produce more antibodies when needed.
Want to catch up on the best tech news of the day? Access and subscribe to our new youtube channel, Canaltech News. Every day a summary of the main news from the tech world for you!
The research will be used to establish the need for boosting the vaccine in the country, as has already been done in several other countries, especially in the West, in regions where immunization campaigns are more advanced.
While research shows that perhaps boosting can be an effective collective immunization strategy, it is not the priority at the moment. The country has a huge population, and the local government intends to increase the number of people with two doses.
India has 944 million adults, and 60% of them have already received at least one dose of some of the immunizations available there. Only 19% have completed the vaccine regimen.
It is worth noting that India was also the discovery site of the Delta variant of the coronavirus, which caused a violent wave of deaths around May 2021 and has now become dominant worldwide. Today, there are more than 440,000 deaths officially registered in the country.
Did you like this article?
Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.